Press Release
Excellent performance across all areas of the business and accelerating new product sales drive revenue growth of 36%
Basingstoke, UK and Philadelphia, US – February 21, 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 – a year which has seen significant growth in launched products.
Financial Highlights:
2007 Full Year
- Product sales up 41% to ,170m
- New product sales 9m, 23% of product sales(1)
- Total revenues up 36% to ,436m
- Non GAAP Earnings per ADS up 38% to .95
- US GAAP Earnings per ADS down 592% to -.06
- Dividend up 20% (in US$ terms)
Q4 2007
- Product sales up 55% to 1m
- New product sales 0m, 32% of product sales (1)
- Total revenues up 46% to 5m
- Non GAAP Earnings per ADS up 67% to
Press Release
Excellent performance across all areas of the business and accelerating new product sales drive revenue growth of 36%
Basingstoke, UK and Philadelphia, US – February 21, 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 – a year which has seen significant growth in launched products.
Financial Highlights:
2007 Full Year
- Product sales up 41% to $2,170m
- New product sales $489m, 23% of product sales(1)
- Total revenues up 36% to $2,436m
- Non GAAP Earnings per ADS up 38% to $2.95
- US GAAP Earnings per ADS down 592% to -$8.06
- Dividend up 20% (in US$ terms)
Q4 2007
- Product sales up 55% to $661m
- New product sales $210m, 32% of product sales (1)
- Total revenues up 46% to $725m
- Non GAAP Earnings per ADS up 67% to $0.94
- US GAAP Earnings per ADS up 175% to $1.11
Latest Press Releases
- Shire delivers strong quarter driven by $243m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
.94More from DodsAdvertiseSpread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
- US GAAP Earnings per ADS up 175% to .11
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.